<DOC>
	<DOC>NCT00145002</DOC>
	<brief_summary>To test the superiority of VCAP-AMP-VECP regimen over biweekly-CHOP in aggressive ATLL in terms of survival benefit.</brief_summary>
	<brief_title>A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)</brief_title>
	<detailed_description>Nothing to describe.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1. Diagnosis of ATL was made based on seropositivity for HTLVI by either enzymelinked immunosorbent assay or particle agglutination assay, and histologically and/or cytologicallyproven peripheral Tcell malignancy 2. Aggressive ATL, i.e., acute, lymphoma or unfavorable chronictype ATL 3. Aged 1569 years 4. No prior chemotherapy or radiotherapy 5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 03 or 4 as a result of hypercalcemia 6. Preserved organ (bone marrow, liver, kidney, heart and lung) functions 7. All patients were required to provide written informed consent 1. Diabetes mellitus necessitating treatment with insulin 2. Active systemic infection 3. Cardiac disorders expected to become worse as a result of the DOXcontaining regimen 4. Acute hepatitis, chronic hepatitis or liver cirrhosis 5. Positive for HBs Ag or antiHCV Ab 6. Active concurrent malignancy 7. Other serious medical or psychiatric conditions 8. Pregnancy or breast feeding 9. Central nervous system involvement by ATL cells</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>ATLL</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>phase III study</keyword>
	<keyword>VCAP-AMP-VECP</keyword>
	<keyword>biweekly-CHOP</keyword>
</DOC>